Phase II Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium in Patients With Non-Invasive Urothelial Carcinoma in Situ (CIS) Previously Treated With Bacille Calmette-Guerin (BCG)

Trial Profile

Phase II Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium in Patients With Non-Invasive Urothelial Carcinoma in Situ (CIS) Previously Treated With Bacille Calmette-Guerin (BCG)

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jul 2015

At a glance

  • Drugs Oportuzumab monatox (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Sponsors Viventia Biotechnologies
  • Most Recent Events

    • 02 Jul 2015 According to Viventia Biotechnologies media release, clinical results were published in the Journal of Urology.
    • 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top